BTX - Brooklyn ImmunoTherapeutics reports results of IRX-2 monotherapy in early stage breast cancer

Brooklyn ImmunoTherapeutics (BTX) announces a publication in Breast Cancer Research that demonstrates how multiplex immunofluorescence (mIF) may be used to characterize the immunological activity of IRX-2 in early stage breast cancer.Multiplex immunofluorescence combined with hierarchical linear modelling resulted in more precise estimates of treatment-related increases in stromal tumor infiltrating lymphocytes, PD-L1, and other metrics such as CD8+ tumor nest infiltration compared to conventional testing.Hierarchical linear modeling can mitigate the effects of intratumoral heterogeneity on immune cell count estimations, thereby allowing to detect treatment-related pharmocodynamic effects of an anticancer drug such as IRX-2, demonstrate treatment activity, and ultimately patient benefit more efficiently. The paper illustrates that IRX-2 increases immune cell infiltration and PD-L1 expression, suggesting that IRX-2 may hold promise in combination of PD-L1-targeted therapy in early stage breast cancer.

For further details see:

Brooklyn ImmunoTherapeutics reports results of IRX-2 monotherapy in early stage breast cancer